Innate Pharma Employees 2024

Innate Pharma Aktienanalyse

What does Innate Pharma do?

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Innate Pharma's Employee Base

Innate Pharma's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Innate Pharma's operational capacity and future potential.

Year-to-Year Comparison

Assessing Innate Pharma's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Innate Pharma's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Innate Pharma’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Innate Pharma stock

How many employees does Innate Pharma have this year?

Innate Pharma has 235 undefined employees this year.

How many employees did Innate Pharma have compared to the previous year?

Compared to the previous year, Innate Pharma had 0% more employees.

What impact did the number of employees have on the company Innate Pharma?

The number of employees has a direct impact on the efficiency and productivity of Innate Pharma. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Innate Pharma?

The number of employees can also have an impact on investors of Innate Pharma, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Innate Pharma affect the company?

An increase in equity of Innate Pharma can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Innate Pharma's equity affect the company?

A reduction in equity of Innate Pharma can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Innate Pharma?

Some factors that can influence the equity of Innate Pharma include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Innate Pharma so important for investors?

The equity of Innate Pharma is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Innate Pharma influence the company?

The number of employees at Innate Pharma can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Innate Pharma evolved in recent years?

In recent years, the number of employees at Innate Pharma has changed by 0.

How many employees does Innate Pharma currently have?

Innate Pharma currently has 235 undefined employees.

Why is the number of employees important for investors of Innate Pharma?

The number of employees is important for investors of Innate Pharma as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Innate Pharma take to change the number of employees?

To change the number of employees, Innate Pharma can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Innate Pharma pay?

Over the past 12 months, Innate Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innate Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Innate Pharma?

The current dividend yield of Innate Pharma is .

When does Innate Pharma pay dividends?

Innate Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innate Pharma?

Innate Pharma paid dividends every year for the past 0 years.

What is the dividend of Innate Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innate Pharma located?

Innate Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innate Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innate Pharma from 9/22/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Innate Pharma pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Innate Pharma in the year 2023?

In the year 2023, Innate Pharma distributed 0 EUR as dividends.

In which currency does Innate Pharma pay out the dividend?

The dividends of Innate Pharma are distributed in EUR.